DCI Scientific Retreat Slated for Oct. 23 (Virtual)

Tyler Jacks, PhD
Tyler Jacks, PhD

Duke faculty, trainees (students, residents, fellows, postdocs, etc.) and staff are invited to the 7th Annual DCI Scientific Retreat, to be held via Zoom on Friday, October 23, 2020, from 12:30 p.m. to 5 p.m.

The *O. Michael Colvin Memorial Lecture —  “Dissecting tumor evolution at single cell resolution" — will be delivered this year by Tyler Jacks, PhD. Jacks is David H. Koch Professor and the director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), and an investigator at the Howard Hughes Medical Institute.

The Jacks Laboratory studies the genetic events underlying the development of cancer. Jacks has pioneered the use of gene targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types, including cancers of the lung, pancreas, colon, and soft tissue. These powerful and sophisticated models closely recapitulate human disease and have led to novel insights into tumor development as well as new strategies for cancer detection and treatment.

More recently, the Jacks group has begun using these advanced models to investigate how immune and tumor cells interact during tumor development, and how tumor immune responses affect the development of cancer in mice.

Jacks received his doctorate from the University of California, San Francisco, where he trained with Nobel Laureate Harold Varmus. He was a post­doctoral fellow with Robert Weinberg at the Whitehead Institute before he joined the MIT faculty in 1992.

In recognition of his contributions to the study of cancer genetics, Jacks has served as Chair of the National Cancer Advisory Board at the National Cancer Institute, was a member of the Board of Directors of the American Association for Cancer Research (AACR), and was elected President of the AACR in 2009. He has been elected to the National Academy of Sciences, the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences, and the inaugural class of Fellows of the AACR Academy.

In 2015, he was the recipient of the Killian Award, the highest honor the MIT faculty can bestow upon one of its members. Jacks serves on the Board of Directors of Thermo Fisher Scientific and Amgen, and is also a co-founder of T2 Biosystems and Dragonfly Therapeutics as well as a scientific advisor to Skyhawk Therapeutics, SQZ Biotech, and the Lustgarten Foundation.

Scott Antonia, MD, PhD, at 2019 DCI Scientific Retreat
Scott Antonia, MD, PhD, at the 2019 DCI Scientific Retreat. Antonia is this year's faculty presenter.

This year's DCI Scientific Retreat faculty presentation will be delivered by Scott Antonia, MD, PhD, a thoracic medical oncologist, professor of Medicine, and director of the DCI Center for Cancer Immunotherapy.

New this year, each of the eight DCI Research Programs has selected a trainee from their program to present on their research project.

The DCI Research Programs — basic, clinical and translational NCI-Designated Programs — include the following:


After presenting, the trainees will have the opportunity to take questions from their mentors and peers.

*Before his loss in 2013, O. Michael Colvin, MD, served as Director Emeritus of the Duke University Comprehensive Cancer Center and Professor Emeritus of Medicine at Duke University School of Medicine. Colvin was a founding senior editor of Molecular Cancer Therapeutics. His many achievements included pioneering work on drugs that damage the genetic material causing cancer cells to replicate. He was one of the first researchers to use high-dose cyclophosphamide to treat solid tumors. Colvin was co-leader of the Duke Cancer Center’s Experimental Research Program. Over the course of his career, he published more than 150 scientific articles. Begun in 2015, the O. Michael Colvin Memorial Lecture has been a featured highlight at every DCI Scientific Retreat since.